How do you approach chemotherapy-induced thrombocytopenia in patients who do not respond adequately to romiplostim?

That's definitely a difficult and highly nuanced clinical scenario, especially since it can hamper future delivery of chemotherapy and compromise disease outcomes. My approach to this question also depends on whether we are talking about patients with a hematologic or solid tumor malignancy. I will ...